Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W7UN
|
|||
| Former ID |
DNCL003147
|
|||
| Drug Name |
BI-409306
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1], [2] | |
| Psychiatric disorder [ICD-11: 6E8Z] | Phase 2 | [3] | ||
| Schizophrenia [ICD-11: 6A20] | Phase 2 | [4] | ||
| Company |
Boehringer Ingelheim Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H17N5O2
|
|||
| Canonical SMILES |
C1COCCC1N2C3=C(C=N2)C(=O)NC(=N3)CC4=CC=CC=N4
|
|||
| InChI |
1S/C16H17N5O2/c22-16-13-10-18-21(12-4-7-23-8-5-12)15(13)19-14(20-16)9-11-3-1-2-6-17-11/h1-3,6,10,12H,4-5,7-9H2,(H,19,20,22)
|
|||
| InChIKey |
BZTIJCSHNVZMES-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1189767-28-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 9 (PDE9) | Target Info | Inhibitor | [5] |
| KEGG Pathway | Purine metabolism | |||
| Pathway Interaction Database | Regulation of Androgen receptor activity | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02240693) Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of Boehringer Ingelheim pipeline. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.